- Home
- Clinical Fields
- Neurology
- Navigating the Evolving Course of Alzheimer's Disease Management

Navigating the Evolving Course of Alzheimer's Disease Management
Expert Interview
- Chapters
- descriptions off, selected
- captions settings, opens captions settings dialog
- captions off, selected
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
Understanding Alzheimer's with Dr. Ana Franceschi
In this exclusive interview, Dr. Ana Franceschi, a top neuroradiologist at Lenox Hill Hospital, shares her latest insights into Alzheimer’s disease, exploring current research, treatments, and the future of neuroimaging. Discover her expert perspective and personal journey in this exclusive video interview on this complex condition.

There are three main factors impacting how you screen, diagnose, and treat patients with Alzheimer’s Disease
-
Increased disease prevalence
-
Emerging new therapies
-
Changing reimbursements
Taken together, these factors can significantly impact your patient care strategy.
Subscribe today
100 Million People
By 2050, 100 million people may have dementia.1 Screening for Alzheimer’s Disease and differentiating it from other dementia forms will be essential to patient care.

Misdiagnosed
1 in 5 Alzheimer’s cases may be misdiagnosed.2 Alzheimer's disease is often misdiagnosed, possibly causing undue stress for those who don't have the disease but are told they do, and delays in treatment for others.

ARIA Incidence
New disease modifying therapies for Alzheimer's disease have emerged. However, the rate of incidence of their well known side effect, Amyloid Related Imaging Abnormalities (ARIA), was 10-30% in clinical trials.3 Therapeutic monitoring will be key to patient safety.
Welcome to the Alzheimer's Disease Resource Hub
Here you will find a collection of valuable resources designed to support healthcare professionals in diagnosing, treating, and managing Alzheimer's Disease. Explore our comprehensive guides and research papers to stay informed about the latest trends and advancements in Alzheimer's care.

Understanding Alzheimer’s Disease
Trends in incidence, diagnosis, and treatment of Alzheimer’s Disease

Pharmaceutical Interventions
Know your FDA-approved Pharmaceutical Interventions for Alzheimer’s Disease

Imaging & Diagnosis
- Amyloid-Related Imaging Abnormalities (ARIA)
- The role of Amyloid and Tau PET Imaging in Dementia

Access and Services
4 ways to provide access to imaging services for your patient
4 ways to support your patients’ care pathway
Optimize patient journeys, reduce costs, and leverage emerging therapies, technologies, and solutions by working with an experienced partner who understands the complete care pathway.
-
Increase screening capabilities
Increase screening capabilities: through widely available lab tests -
Support differential diagnosis
Support differential diagnosis: through enhanced MR imaging and quantitative assessment of brain regions -
Perform Amyloid assessment & determine therapy eligibility
Perform Amyloid assessment & determine therapy eligibility: via accurate confirmation of amyloid plaque burden through PET/CT and PET/MR imaging (with timely access to Radiopharmaceuticals). -
Monitor therapy
Monitor therapy: through enhanced MR imaging of amyloid-related imaging abnormalities (ARIA)
Now more than ever, working with an experienced partner who understands the complete care pathway may help you optimize patient journeys, reduce costs, and leverage emerging therapies, technologies, and solutions.
Expanding access to care with a comprehensive portfolio for Alzheimer's disease management
Magnetic Resonance Imaging
MAGNETOM Portfolio of scanners
Enabling accurate differential diagnosis and efficient treatment monitoring.
Learn More About Magnetic Resonance ImagingAI for Imaging Decision Support
AI-Rad Companion Brain MR
Brain morphometry tools for quantitative assessment of brain regions and help detect changes.
Learn More About AI for Imaging Decision SupportPET/CT
Biograph™ family of scanners
Early visualization and quantification of amyloid burden.
Learn More About PET/CTAmyloid & Tau Imaging Agents
PETNET Solutions, Inc.
Large network of radiopharmacies distributing amyloid tracers.
Learn More About Amyloid & Tau Imaging AgentsEnterprise Imaging
Syngo Carbon
Connects all imaging disciplines into one workplace.
Learn More About Enterprise ImagingQuantitative Accuracy
syngo.via MI Neurology
Provides both quantification and databases for your patient population.
Learn More About Quantitative AccuracyLaboratory Diagnostics
Atellica® Solution
Laboratory testing.
Learn More About Laboratory DiagnosticsAI for MRI
AI for MRI
AI-driven workflow along the whole MRI imaging path.
Learn More About AI for MRIPET/MR
Biograph™ mMR
Potential for a more complete imaging picture & a better understanding of neurologic pathologies.
Learn More About PET/MR
Download our quick guide for more information about Alzheimer’s Disease.
Discover the impact of AD.
Learn More TodayPlease complete the form below to be included in future email communications
By completing the form below, you are requesting to be added to our list for email communications. The information you provide below will be processed as described further in the Privacy Notice.